Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
Incyte (INCY) Gets CRL for Jakafi Extended-Release Tablets
08:26am, Friday, 24'th Mar 2023
The FDA issues a complete response letter to Incyte's (INCY) extended-release tablet formulation of Jakafi drug for the treatment of myelofibrosis, polycythemia vera and graft-versus-host disease.
Incyte (INCY) Receives FDA Approval for Skin Cancer Treatment
01:44pm, Thursday, 23'rd Mar 2023
Incyte (INCY) gets accelerated approval for retifanlimab-dlwr for the treatment of adults with metastatic or recurrent locally advanced merkel cell carcinoma.
7 Healthcare Stocks to Buy for Long-Term Growth and Stability
04:13pm, Tuesday, 21'st Mar 2023
Stock market investors have been on a rollercoaster ride over the past year. The Federal Reserve continues to be hawkish in controlling inflation.
Incyte (INCY) Vitiligo Drug Povorcitinib Positive in Phase II
12:59pm, Monday, 20'th Mar 2023
Incyte (INCY) announces positive data on povorcitinib and Opzelura for the treatment of nonsegmental vitiligo.
Incyte (INCY) Discontinues Jakafi Combo Myelofibrosis Study
11:17am, Tuesday, 07'th Mar 2023
Incyte (INCY) decides to scrap the LIMBER-304 study evaluating the efficacy and safety of parsaclisib plus Jakafi for myelofibrosis (MF) following an independent data monitoring committee recommendati
10 S&P 500 Stocks Are Practically Immune To More Fed Rate Hikes
08:00am, Monday, 06'th Mar 2023
Is the Fed done jacking up interest rates or not? Angst over that question is torturing the stock market — but a handful of S&P 500 stocks aren't worried.
Incyte (INCY) Reports Positive Long-Term Data From HS Study
01:33pm, Monday, 13'th Feb 2023
Incyte's (INCY) povorcitinib shows sustained and durable efficacy across all treatment arms in the open-label extension period of the phase II HS study.
Markets Rise on Powell's Inflation Comments
05:50pm, Tuesday, 07'th Feb 2023
U.S. equities posted gains on Feb. 7 after Fed Chair Jerome Powell said that inflation was easing but noted that rate hikes would continue if needed.
Incyte Corporation (INCY) Q4 2022 Earnings Call Transcript
12:11pm, Tuesday, 07'th Feb 2023
Incyte Corporation (NASDAQ:INCY ) Q4 2022 Earnings Conference Call February 7, 2023 8:00 AM ET Company Participants Christine Chiou - Head, Investor Relations Hervé Hoppenot - Chairman, President and
Incyte's (INCY) Q4 Earnings, Revenues Top on Jakafi, Opzelura
12:03pm, Tuesday, 07'th Feb 2023
Incyte (INCY) reports better-than-expected Q4 results on strong demand for lead drug Jakafi and recently approved Opzelura.
Incyte, Haemonetics Post Earnings Beats; One Surges Within Buy Zone
10:05am, Tuesday, 07'th Feb 2023
Incyte stock fell Tuesday after topping quarterly expectations, while fellow medical outlet Haemonetics leapt on its own beat-and-raise. The post Incyte, Haemonetics Post Earnings Beats; One Surges Wi
Incyte (INCY) Tops Q4 Earnings and Revenue Estimates
09:47am, Tuesday, 07'th Feb 2023
Incyte (INCY) delivered earnings and revenue surprises of 5.08% and 4.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
3 Reasons Why Growth Investors Shouldn't Overlook Incyte (INCY)
02:18pm, Wednesday, 01'st Feb 2023
Incyte (INCY) could produce exceptional returns because of its solid growth attributes.
Incyte (INCY) is a Great Momentum Stock: Should You Buy?
01:33pm, Friday, 27'th Jan 2023
Does Incyte (INCY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Incyte: Opzelura Is The Main Growth Driver
09:24am, Tuesday, 24'th Jan 2023
Opzelura's approval in vitiligo in the USA is the main growth driver. Next driver is Opzelura's approval for the vitiligo treatment in Europe. The issue with Jakafi's LOE may be solved by the developm
